Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).Hedyeh Ebrahimi, Alex Chehrazi‐Raffle, Luís Meza et al.|Journal of Clinical Oncology|2025Cited by 1
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.Salvador Jaime-Casas, Abhishek Tripathi, Nicholas Salgia et al.|Journal of Clinical Oncology|2026Cited by 0
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).Benjamin Mercier, Sumanta Kumar Pal, Vitor Góes et al.|Journal of Clinical Oncology|2026Cited by 0
Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing <i>ALK</i> alteration prolongs treatment duration.Vitor Góes, Sumanta Kumar Pal, Miguel Zugman et al.|Cancer Research|2026Cited by 0